Recently, the infusion of recombinant apoA1 (CSL112) in people with existing ASCVD did not reduce risk of major adverse cardiovascular events (MACEs) within 3 months [103], further raising doubt about the cardioprotective effects of HDL. Here, APOA1 is linked to atherosclerosis.